BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 28581505)

  • 1. A decade of discovery: CRISPR functions and applications.
    Barrangou R; Horvath P
    Nat Microbiol; 2017 Jun; 2():17092. PubMed ID: 28581505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR-Cas in the laboratory classroom.
    Trudel L; Frenette M; Moineau S
    Nat Microbiol; 2017 Feb; 2():17018. PubMed ID: 28211845
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulation of CRISPR-Cas adaptive immune systems.
    Patterson AG; Yevstigneyeva MS; Fineran PC
    Curr Opin Microbiol; 2017 Jun; 37():1-7. PubMed ID: 28359988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas: from adaptive immune system in prokaryotes to therapeutic weapon against immune-related diseases.
    Garcia-Robledo JE; Barrera MC; Tobón GJ
    Int Rev Immunol; 2020; 39(1):11-20. PubMed ID: 31625429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diversity and evolution of class 2 CRISPR-Cas systems.
    Shmakov S; Smargon A; Scott D; Cox D; Pyzocha N; Yan W; Abudayyeh OO; Gootenberg JS; Makarova KS; Wolf YI; Severinov K; Zhang F; Koonin EV
    Nat Rev Microbiol; 2017 Mar; 15(3):169-182. PubMed ID: 28111461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas Technologies and Applications in Food Bacteria.
    Stout E; Klaenhammer T; Barrangou R
    Annu Rev Food Sci Technol; 2017 Feb; 8():413-437. PubMed ID: 28245154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next Generation Prokaryotic Engineering: The CRISPR-Cas Toolkit.
    Mougiakos I; Bosma EF; de Vos WM; van Kranenburg R; van der Oost J
    Trends Biotechnol; 2016 Jul; 34(7):575-587. PubMed ID: 26944793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9: From a bacterial immune system to genome-edited human cells in clinical trials.
    Kick L; Kirchner M; Schneider S
    Bioengineered; 2017 May; 8(3):280-286. PubMed ID: 28287876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas Biology and Its Application to Infectious Diseases.
    Strich JR; Chertow DS
    J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30429256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diversity, classification and evolution of CRISPR-Cas systems.
    Koonin EV; Makarova KS; Zhang F
    Curr Opin Microbiol; 2017 Jun; 37():67-78. PubMed ID: 28605718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cas spacers in orphan CRISPR4 arrays prevent uptake of active CRISPR-Cas I-F systems.
    Almendros C; Guzmán NM; García-Martínez J; Mojica FJ
    Nat Microbiol; 2016 Jun; 1(8):16081. PubMed ID: 27573106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type III CRISPR-Cas systems: when DNA cleavage just isn't enough.
    Pyenson NC; Marraffini LA
    Curr Opin Microbiol; 2017 Jun; 37():150-154. PubMed ID: 28865392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene regulation by engineered CRISPR-Cas systems.
    Fineran PC; Dy RL
    Curr Opin Microbiol; 2014 Apr; 18():83-9. PubMed ID: 24637219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of CRISPR in archaea and bacteria.
    Mojica FJ; Rodriguez-Valera F
    FEBS J; 2016 Sep; 283(17):3162-9. PubMed ID: 27234458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the Origin of CRISPR-Cas Technology: From Prokaryotes to Mammals.
    Mojica FJM; Montoliu L
    Trends Microbiol; 2016 Oct; 24(10):811-820. PubMed ID: 27401123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CRISPR Growth Spurt: from Bench to Clinic on Versatile Small RNAs.
    Bayat H; Omidi M; Rajabibazl M; Sabri S; Rahimpour A
    J Microbiol Biotechnol; 2017 Feb; 27(2):207-218. PubMed ID: 27840399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visualization analysis of CRISPR/Cas9 gene editing technology studies.
    Du QS; Cui J; Zhang CJ; He K
    J Zhejiang Univ Sci B; 2016 Oct.; 17(10):798-806. PubMed ID: 27704749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immune system of prokaryotes: potential applications and implications for gene editing.
    Liu S; Liu H; Wang X; Shi L
    Biotechnol J; 2024 Feb; 19(2):e2300352. PubMed ID: 38403433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas Systems in Prokaryotes.
    Burmistrz M; Pyrć K
    Pol J Microbiol; 2015; 64(3):193-202. PubMed ID: 26638527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A New Class of Medicines through DNA Editing.
    Porteus MH
    N Engl J Med; 2019 Mar; 380(10):947-959. PubMed ID: 30855744
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 32.